|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:adjuvant
|
gptkb:CpG_1018
aluminum hydroxide
|
|
gptkbp:age
|
18 years and older
|
|
gptkbp:alsoKnownAs
|
gptkb:MVC-COV1901
|
|
gptkbp:antigen
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:approvedBy
|
gptkb:Eswatini
gptkb:New_Zealand
gptkb:Paraguay
gptkb:Taiwan
gptkb:Somaliland
2021-07-19
|
|
gptkbp:boosterInterval
|
at least 12 weeks after second dose
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Paraguay
gptkb:Taiwan
Phase 2
Phase 3
|
|
gptkbp:collaboratesWith
|
gptkb:US_National_Institutes_of_Health
gptkb:Dynavax_Technologies
|
|
gptkbp:compatibleWith
|
gptkb:US_FDA
gptkb:European_Medicines_Agency
|
|
gptkbp:countryOfOrigin
|
gptkb:Taiwan
|
|
gptkbp:developedBy
|
gptkb:Medigen_Vaccine_Biologics_Corporation
|
|
gptkbp:efficacyData
|
immunobridging study
|
|
gptkbp:emergencyServices
|
gptkb:Taiwan
|
|
gptkbp:emergencyUseAuthorizationDate
|
2021-07-19
|
|
gptkbp:form
|
two doses
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Medigen COVID-19 vaccine
|
|
gptkbp:intervalBetweenDoses
|
28 days
|
|
gptkbp:platform
|
gptkb:protein
|
|
gptkbp:regulates
|
gptkb:emergency_use_authorization
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
diarrhea
fatigue
headache
joint pain
muscle pain
chills
injection site pain
allergic reaction (rare)
mild to moderate
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
protein subunit vaccine
|
|
gptkbp:usedInNationalVaccinationProgram
|
gptkb:Taiwan
|
|
gptkbp:WHOEmergencyUseListing
|
not listed
|
|
gptkbp:bfsParent
|
gptkb:MVC-COV1901
|
|
gptkbp:bfsLayer
|
8
|